VBIOHealthcare · Biotechnology

VBIO Stock Forecast: Valion Bio, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026

$1.45

−6.77% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 13 Oct 2026 — in the weakest quartile.

Market cap

$2.8M

Ticker Nerd rank

2 / 100

Median analyst target

—

Analysts covering

Revenue$0.0−100.0% y/y

Operating income−$6.4M

Net income−$7.1M

Free cash flow−$5.3M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−34.0%

−31.2%

YTD

−96.0%

−98.1%

From 52W high

−98.1%

From 52W low

0.0%

$75

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

VBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Valion Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026

2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Volatility

Revisions

Accruals

Growth

Value

Quality

Momentum

Issuance

Size (97): Smaller than most of the companies we track.

Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VBIO appears on the weeks it earns a place.

Performance

VBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Valion Bio, Inc. returned −98.1% against +17.5% for the S&P 500, dividends included.

VBIO vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Valion Bio, Inc. (VBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.0×
Price / sales: −32.8×
Price / book: 0.1×
EV / EBITDA: −1.0×

Growth & margins

Revenue growth (YoY): −100.0%
Earnings growth (YoY): −100.0%
Gross margin: —
Operating margin: 19652.3%
Net margin: 0.0%

Returns & dividend

Return on equity: −459.5%
Return on assets: −57.1%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Valion Bio, Inc. (VBIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Valion Bio, Inc. has a market value of $2.8M and an enterprise value of $16.7M.
Revenue in the twelve months to 30 June 2026: −$156K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$18.8M, a 12019.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$14.7M.
Shares outstanding: 166,076.
Trailing P/E: −0.0×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Valion Bio, Inc. employs 52 people — −$3K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

VBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
VBIOValion Bio, Inc.	$2.8M	2
XRTXXORTX Therapeutics, Inc.	$3.1M	11
DCOYDecoy Therapeutics, Inc.	$3.0M	21
APVOAptevo Therapeutics, Inc.	$3.1M	29
ONCOOnconetix, Inc.	$2.9M	18
VIVSVivoSim Labs, Inc.	$2.9M	38
CMNDClearmind Medicine, Inc.	$3.2M	7

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Valion Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VBIO news & analysis

With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge

Accesswire · 14 Oct 2026positive

Valion Bio highlighted capabilities at its wholly owned Velocity Bioworks facility in San Antonio, including process development, analytical services, and early-phase clinical drug substance manufacturing for companies evaluating U.S.-based production. Velocity also supports Valion’s development strategy for Entolimod, its potential medical countermeasure for Acute Radiation Syndrome.

Why it matters — The facility’s services and role in Valion’s domestic biologics supply chain are relevant to watchers assessing the company’s manufacturing capabilities and support for Entolimod development.

Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers

Accesswire · 9 Oct 2026positive

Valion Bio said it is developing an oral mucosal formulation of Entolimod that could offer needle-free administration for acute radiation syndrome. The company cited growing electricity demand from AI and data centers, and potential nuclear-power expansion, as reasons to emphasize scalable civilian radiation preparedness.

Why it matters — VBIO watchers may note the company’s potential needle-free delivery approach as it develops a medical countermeasure for radiological or nuclear emergencies.

New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod

Accesswire · 5 Oct 2026positive

Valion Bio introduced its new Board Chair, Thomas H. Jensen, who shared his perspectives on advancing the company's lead candidate Entolimod. Jensen previously led Nasdaq-listed Allarity Therapeutics through a refocusing around a single lead asset and noted Valion's combination of government funding, FDA designations, human safety data, and wholly owned U.S. manufacturing.

Why it matters — Valion watchers would care because Jensen's stated biotech turnaround experience may inform how the company advances Entolimod, and his focus on Valion's government funding and regulatory designations highlights potential strengths in its development approach.

Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity

Accesswire · 30 Sept 2026positive

Valion Bio and Shear Kershman Laboratories announced successful completion of formulation work on an oral mucosal formulation of Entolimod, Valion's investigational radiation-protection biologic, using SKL's BioViscid drug-delivery platform. The needle-free program creates a potential second development pathway alongside Valion's injectable Entolimod, with the next study testing whether the formulation delivers measurable amounts of Entolimod into the bloodstream.

Why it matters — A VBIO watcher would care because a successful oral mucosal formulation could create a second delivery pathway for Entolimod and expand the company's long-term opportunity beyond its injectable program.

Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions

Accesswire · 23 Sept 2026neutral

Valion Bio announced executive leadership and Board of Directors changes, appointing life sciences veteran Dean Zikria as interim CEO. The Company stated these transitions are intended to strengthen organizational alignment and support execution as it advances Entolimod, its other development programs, and evaluates strategic, commercial, and government opportunities.

Why it matters — VBIO watchers would care because a new interim CEO and board leadership transitions could affect how the Company manages its Entolimod development and strategic planning.

FAQ

Frequently asked questions about VBIO stock

How does Ticker Nerd's model rank VBIO?

As at 13 Oct 2026, Valion Bio, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the VBIO stock forecast for 2030?

No analyst covering Valion Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VBIO are extrapolating price history, which says nothing about the business.

How has VBIO stock performed over the past year?

Valion Bio, Inc. returned -98.1% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Valion Bio, Inc. do?

Valion Bio, Inc. operates as a late-stage biopharmaceutical company.

What is the latest news on VBIO?

The most recent item we track (Accesswire, 14 Oct 2026): "With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge". Valion Bio highlighted capabilities at its wholly owned Velocity Bioworks facility in San Antonio, including process development, analytical services, and early-phase clinical drug substance manufacturing for companies evaluating U.S.-based production. Velocity also supports Valion’s development strategy for Entolimod, its potential medical countermeasure for Acute Radiation Syndrome.

Company

About Valion Bio, Inc.

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

CEO Mr. J. Dean Zikria · 52 employees · United States · https://valionbio.com